Patients with proposed diagnostic or simple therapeutic painless bronchoscopy
Conditions
Interventions
Male group:The dose of intravenous oliceridine in the first patient was set at 40 µg·kg-1. Subsequent patients were adjusted according to the response of the previous patient, and the dose of the next
Female group:The dose of intravenous oliceridine in the first patient was set at 40 µg·kg-1. Subsequent patients were adjusted according to the response of the previous patient, and the dose of the ne
Sponsors
The Affiliated Hospital of Guizhou Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Age 18-65 years, ASA classification I-III. 2. Patients for whom painless bronchoscopy or simple treatment is proposed. 3. Body mass index (BMI) 18 -28 kg/m². 4. Signed informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients with known hypersensitivity to remimazolam, oliceridine or its components. 2. Patients with anticipated difficult airways. 3. Patients with severe hypertension (systolic blood pressure >= 180 mmHg, or diastolic blood pressure >= 110 mmHg). 4. Patients with severely impaired hepatic or renal function (Child-Pugh class C, or eGFR 2 weeks).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ED50 and ED95 of Oxalidine Fumarate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Haemodynamic changes;Incidence of respiratory depression;Total amount of vasoactive drugs used;Patient satisfaction;Operator satisfaction;recovery time;Incidence of postoperative nausea and vomiting;Rescue of analgesic drugs; | — |
Countries
China
Contacts
Public ContactAnhong Li
The Affiliated Hospital of Guizhou Medical University
Outcome results
None listed